Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Globe Investor

Inside the Market

Up-to-the-minute insights
on developing market news

Entry archive:

Three investing lessons to be learned from Valeant’s stunning fall from grace Add to ...

Subscribers Only

The most amazing aspect of the troubles at Valeant Pharmaceutical International Inc. is that they are anything but amazing for those who have been following the company.

Analysts, most notably Dimitry Khmelnitsky at Veritas Investment Research in Toronto, started sounding alarms about the drug-maker’s accounting as far back as 2011.

Report Typo/Error

Follow on Twitter: @IanMcGugan

Also on The Globe and Mail

Valeant hires former Zoetis CFO in latest executive shakeup (BNN Video)

Next story